Urokinase API: A Time-Tested Thrombolytic Material

Urokinase, a urinary-derived enzyme, has been a mainstay in the treatment of acute thromboembolic disorders for decades. As an active pharmaceutical ingredient, urokinase works by directly converting plasminogen to plasmin, thereby dissolving fibrin clots in conditions such as pulmonary embolism, deep vein thrombosis, and acute myocardial infarction.

What makes urokinase valuable as an API intermediate is its rapid onset of action and relatively short half-life (10–20 minutes). Compared to streptokinase, urokinase is less immunogenic and does not cause widespread allergic reactions. Compared to recombinant tissue plasminogen activator (rt-PA), urokinase is significantly more affordable, making it the preferred thrombolytic in many public healthcare systems.

As cardiovascular diseases remain the leading cause of death worldwide, the demand for affordable thrombolytic APIs like urokinase will continue. We welcome inquiries from formulators seeking a reliable, high-purity urinary source.